NCT06684964View on ClinicalTrials.gov

RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)

RecruitingOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2026

Conditions
Chronic Myelogenous Leukemia in Chronic Phase
Interventions
OTHER

asciminib

This is an observational study. There is no treatment allocation. The decision to initiate asciminib will be based solely on clinical judgement.

Trial Locations (2)

11426

RECRUITING

Novartis Investigative Site, Riyadh

21423

RECRUITING

Novartis Investigative Site, Jeddah

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY